UNICREDIT BANK/CALL/AMGEN/420/0.1/15.01.25

UNICREDIT BANK/CALL/AMGEN/420/0.1/15.01.25 Share Price

DE000HD21R79

Market Closed - Boerse Frankfurt Warrants 18:25:07 31/05/2024 BST
0.33 ^EUR	+3.12%

1 month	+175.00%
3 months	+135.71%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Chart UNICREDIT BANK/CALL/AMGEN/420/0.1/15.01.25

Latest news about AMGEN INC.

Amgen : 2024 Annual Meeting of Stockholders Presentation	05-31	PU
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	05-28	RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	05-28	DJ
Weight-loss drug forecasts jump to $150 billion as supply grows	05-28	RE

More news

Quotes 5-day view

Date	Price	Change
31/05/24	0.33	+3.13%
30/05/24	0.32	+14.29%
29/05/24	0.28	-3.45%
28/05/24	0.29	-19.44%
27/05/24	0.36	-7.69%

Real-time Boerse Frankfurt Warrants

Last update May 31, 2024 at 06:25 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	UniCredit
WKN	HD21R7
ISIN	DE000HD21R79
Date issued	23/01/2024
Strike	420 $
Maturity	15/01/2025 (228 Days)
Parity	10 : 1
Emission price	0.59 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	0.8 €
Lowest since issue	0.007 €
Delta	0.12x
Omega	9.567
Premium	38.79x
Gearing	79.29x
Moneyness	0.7271
Difference Strike	114.2 $
Difference Strike %	+27.19%
Spread	0.03 €
Spread %	8.11%
Theoretical value	0.3550
Implied Volatility	29.31 %
Total Loss Probability	91.84 %
Intrinsic value	0.000000
Present value	0.3550
Break even	423.85 €
Theta	-0.02x
Vega	0.04x
Rho	0.02x

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company